Search PubMed⌕ Search

Biomedical subjects

H Varmus

Publications and source records attributed to H Varmus.

At least 19 recordsLinked to original sources

Oncogenes come of age.

Mutations of proto-oncogenes are common events in the pathogenesis of cancers, as shown in a wide range of studies during the 30 years since the discovery of these genes. The benefits of novel therapies that target the products of mutant alleles in human cancers, and the demonstrated dependence of cancers in mouse models on continued expression of initiating oncogenes, are especially promising signs that revolutionary improvements in cancer care are possible. Full realization of the promise of targeted therapies, however, will require better definitions of the genotypes of human cancers, new approaches to interrupt the biochemical consequences of oncogenic mutations, and a greater understanding of drug resistance and tumor progression. In this paper, we summarize recent efforts toward these goals in our laboratory and others.

Adenocarcinoma↗

Public health. Grand Challenges in Global Health.

This week an international panel announces a list of 14 Grand Challenges in Global Health, and scientists throughout the world will be invited to submit grant proposals to pursue them with funds provided by the Bill and Melinda Gates Foundation. We describe the characteristics of these challenges and the process by which they were formulated and selected after receiving over 1000 responses to a "call for ideas" from the scientific community.

Animals↗

Harold Varmus [interview by Karen Birmingham].

He may have stepped away from the hottest seat in biomedical research, but Nobel Laureate Harold Varmus shows no signs of withdrawing from the frontline of the biomedical research community, and he still displays the inimitable combination of political astuteness and scientific expertise that made his reign as director of the United States National Institutes of Health so successful. Varmus spoke to Nature Medicine for the first in a series of profiles that the journal will run on scientists that make a difference to biomedical research.

Cancer Care Facilities↗

Revitalization of the Warren G. Magnuson Clinical Center at the National Institutes of Health.

For nearly 45 years the Warren G. Magnuson Clinical Center has been the site of the intramural clinical research of the National Institutes of Health. It has served as the largest clinical research facility for the nation and the site for training many of the clinical investigators in the nation's academic medical centers. Research at the Clinical Center has focused on study of orphan diseases and phase 1 and 2 clinical trials, and this research emphasis has made it a special national resource. Over the last decade there has been a dramatic decline in the number of patients seen at the Clinical Center, as well as a perceived decrease in the quality of research performed at the center. The decreased activity is related in part to fiscal constraints and the impact of the changing health care delivery system. The trends at the Clinical Center are particularly distributing because they parallel what is happening at academic health centers across the country. Because its success is viewed as vital to national clinical research, a major effort has been undertaken to revitalize the center. This paper reports on the plans and activities undertaken to reorganize the center's management, revitalize its infrastructure for conducting clinical research, establish vital clinical research training, and promote partnerships with extramural investigators who will benefit from access to the center. The hope is that the model established at the NIH Clinical Center will assist in the revitalization of clinical research across the nation.

Clinical Trials as Topic↗

Casein kinase 2 associates with and phosphorylates dishevelled.

The dishevelled (dsh) gene of Drosophila melanogaster encodes a phosphoprotein whose phosphorylation state is elevated by Wingless stimulation, suggesting that the phosphorylation of Dsh and the kinase(s) responsible for this phosphorylation are integral parts of the Wg signaling pathway. We found that immunoprecipitated Dsh protein from embryos and from cells in tissue culture is associated with a kinase activity that phosphorylates Dsh in vitro. Purification and peptide sequencing of a 38 kDa protein co-purifying with this kinase activity showed it to be identical to Drosophila Casein Kinase 2 (CK2). Tryptic phosphopeptide mapping indicates that identical peptides are phosphorylated by CK2 in vitro and in vivo, suggesting that CK2 is at least one of the kinases that phosphorylates Dsh. Overexpression of Dfz2, a Wingless receptor, also stimulated phosphorylation of Dsh, Dsh-associated kinase activity, and association of CK2 with Dsh, thus suggesting a role for CK2 in the transduction of the Wg signal.

Adaptor Proteins, Signal Transducing↗

A member of the Frizzled protein family mediating axis induction by Wnt-5A.

In Xenopus laevis embryos, the Wingless/Wnt-1 subclass of Wnt molecules induces axis duplication, whereas the Wnt-5A subclass does not. This difference could be explained by distinct signal transduction pathways or by a lack of one or more Wnt-5A receptors during axis formation. Wnt-5A induced axis duplication and an ectopic Spemann organizer in the presence of hFz5, a member of the Frizzled family of seven-transmembrane receptors. Wnt-5A/hFz5 signaling was antagonized by glycogen synthase kinase-3 and by the amino-terminal ectodomain of hFz5. These results identify hFz5 as a receptor for Wnt-5A.

Animals↗